Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.

Zhou F, Su C, Liang W, Xu LD, Tao W, Qian J, Xu S, Liu D, Fan R, Zhang Y, Liu Y, Wu L, Fu X, Zhang X, Shen N, Ge D, Chen Q, Mao W, Xu L, Chen C, Hu B, Shao G, Hu J, Zhao J, Liu X, Liu Z, Wang Z, Xiao Z, Gong T, Lin W, Li X, Ye F, Liu Y, Ma H, Huang Y, Zhou J, Wang Z, Fu J, Ding L, Mao L, Chen W, He J, Zhou C

Open source

DOI
10.1038/s41467-026-76392-9
Published
2026 Aug 10
Container
Nature communications
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-76392-9,
  title = {Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.},
  author = {Zhou F and Su C and Liang W and Xu LD and Tao W and Qian J and Xu S and Liu D and Fan R and Zhang Y and Liu Y and Wu L and Fu X and Zhang X and Shen N and Ge D and Chen Q and Mao W and Xu L and Chen C and Hu B and Shao G and Hu J and Zhao J and Liu X and Liu Z and Wang Z and Xiao Z and Gong T and Lin W and Li X and Ye F and Liu Y and Ma H and Huang Y and Zhou J and Wang Z and Fu J and Ding L and Mao L and Chen W and He J and Zhou C},
  year = {2026},
  journal = {Nature communications},
  doi = {10.1038/s41467-026-76392-9},
  url = {https://doi.org/10.1038/s41467-026-76392-9}
}

RIS

TY  - JOUR
TI  - Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.
AU  - Zhou F
AU  - Su C
AU  - Liang W
AU  - Xu LD
AU  - Tao W
AU  - Qian J
AU  - Xu S
AU  - Liu D
AU  - Fan R
AU  - Zhang Y
AU  - Liu Y
AU  - Wu L
AU  - Fu X
AU  - Zhang X
AU  - Shen N
AU  - Ge D
AU  - Chen Q
AU  - Mao W
AU  - Xu L
AU  - Chen C
AU  - Hu B
AU  - Shao G
AU  - Hu J
AU  - Zhao J
AU  - Liu X
AU  - Liu Z
AU  - Wang Z
AU  - Xiao Z
AU  - Gong T
AU  - Lin W
AU  - Li X
AU  - Ye F
AU  - Liu Y
AU  - Ma H
AU  - Huang Y
AU  - Zhou J
AU  - Wang Z
AU  - Fu J
AU  - Ding L
AU  - Mao L
AU  - Chen W
AU  - He J
AU  - Zhou C
PY  - 2026
JO  - Nature communications
DO  - 10.1038/s41467-026-76392-9
UR  - https://doi.org/10.1038/s41467-026-76392-9
ER  -

APA

F, Z., C, S., W, L., LD, X., W, T., J, Q., S, X., D, L., R, F., Y, Z., Y, L., L, W., X, F., X, Z., N, S., D, G., Q, C., W, M., L, X., C, C., B, H., G, S., J, H., J, Z., X, L., Z, L., Z, W., Z, X., T, G., W, L., X, L., F, Y., Y, L., H, M., Y, H., J, Z., Z, W., J, F., L, D., L, M., W, C., J, H., & C, Z. (2026). Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.. Nature communications. https://doi.org/10.1038/s41467-026-76392-9

Source records